Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Allarity Therapeutics, Inc. (ALLR : NSDQ)

• Company Description    Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A. Number of Employees: 7

• Price / Volume Information    Yesterday's Closing Price: $1.00 Daily Weekly Monthly 20 Day Moving Average: 404,875 shares Shares Outstanding: 15.08 (millions) Market Capitalization: $15.08 (millions) Beta: 0.04 52 Week High: $7.38 52 Week Low: $0.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 14.74% 8.98% 12 Week -6.54% -18.60% Year To Date -14.53% -20.17%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 24 SCHOOL ST. 2ND FLOOR - BOSTON,MA 02108 USA ph: 401-426-4664 fax: - investorrelations@allarity.com http://www.allarity.com

• General Corporate Information    Officers Thomas H. Jensen - Chief Executive Officer and Director Gerald W. McLaughlin - Chairman of the Board Alexander Epshinsky - Chief Financial Officer Joseph W. Vazzano - Director Laura E. Benjamin - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 016744500 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 15.08 Most Recent Split Date: 9.00 (0.03:1) Beta: 0.04 Market Capitalization: $15.08 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-46.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.91 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 99.96% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -147.94 12/31/24 - -267.71 ROA 06/30/25 - - 03/31/25 - -90.33 12/31/24 - -114.18 Current Ratio 06/30/25 - - 03/31/25 - 2.66 12/31/24 - 2.06 Quick Ratio 06/30/25 - - 03/31/25 - 2.66 12/31/24 - 2.06 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 1.09 12/31/24 - 1.62 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©